Showing 121 - 140 results of 36,171 for search '(( 19 levels increased ) OR ((( c largest decrease ) OR ( ((a large) OR (b large)) decrease ))))', query time: 1.26s Refine Results
  1. 121

    A super-SILAC based proteomics analysis of diffuse large B-cell lymphoma-NOS patient samples to identify new proteins that discriminate GCB and non-GCB lymphomas by L. E. van der Meeren (7490675)

    Published 2019
    “…<div><p>Diffuse large B-cell lymphoma—not otherwise specified (DLBCL-NOS) is a large and heterogeneous subgroup of non-Hodgkin lymphoma. …”
  2. 122

    Table_2_Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma.pdf by Tianqi Xu (9574329)

    Published 2021
    “…Background<p>Anaplastic diffuse large B-cell lymphoma(A-DLBCL) is a rare morphological subtype characterized by the presence of polygonal, bizarre-shaped tumor cells. …”
  3. 123

    Table_1_Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma.pdf by Tianqi Xu (9574329)

    Published 2021
    “…Background<p>Anaplastic diffuse large B-cell lymphoma(A-DLBCL) is a rare morphological subtype characterized by the presence of polygonal, bizarre-shaped tumor cells. …”
  4. 124

    Prognostic value of lactate dehydrogenase, serum albumin and the lactate dehydrogenase/albumin ratio in patients with diffuse large B-cell lymphoma by Wenke Wu (17665962)

    Published 2023
    “…<p>To investigate the prognostic value of lactate dehydrogenase (LDH), serum albumin (ALB) and the lactate dehydrogenase/albumin ratio (LAR) in diffuse large B-cell lymphoma (DLBCL) before primary treatment.…”
  5. 125
  6. 126
  7. 127
  8. 128
  9. 129
  10. 130

    DataSheet_1_A nationwide analysis of the treatment patterns, survival, and medical costs in Korean patients with relapsed or refractory diffuse large B-cell lymphoma.docx by Jeong-Yeon Cho (11787386)

    Published 2024
    “…Background<p>Approximately one-third of patients with diffuse large B-cell lymphoma (DLBCL) are refractory to treatment or experience relapse after initial therapy. …”
  11. 131
  12. 132
  13. 133
  14. 134
  15. 135
  16. 136

    Image_2_Identification and Assessment of Necroptosis-Related Genes in Clinical Prognosis and Immune Cells in Diffuse Large B-Cell Lymphoma.jpeg by Qikai Zhang (6905096)

    Published 2022
    “…Background<p>With the unveiling of new mechanisms and the advent of new drugs, the prognosis of diffuse large B-cell lymphoma (DLBCL) becomes promising, but some patients still progress to the relapse or refractory stage. …”
  17. 137

    Image_1_Identification and Assessment of Necroptosis-Related Genes in Clinical Prognosis and Immune Cells in Diffuse Large B-Cell Lymphoma.jpeg by Qikai Zhang (6905096)

    Published 2022
    “…Background<p>With the unveiling of new mechanisms and the advent of new drugs, the prognosis of diffuse large B-cell lymphoma (DLBCL) becomes promising, but some patients still progress to the relapse or refractory stage. …”
  18. 138

    Image_4_Identification and Assessment of Necroptosis-Related Genes in Clinical Prognosis and Immune Cells in Diffuse Large B-Cell Lymphoma.jpeg by Qikai Zhang (6905096)

    Published 2022
    “…Background<p>With the unveiling of new mechanisms and the advent of new drugs, the prognosis of diffuse large B-cell lymphoma (DLBCL) becomes promising, but some patients still progress to the relapse or refractory stage. …”
  19. 139

    Image_3_Identification and Assessment of Necroptosis-Related Genes in Clinical Prognosis and Immune Cells in Diffuse Large B-Cell Lymphoma.jpeg by Qikai Zhang (6905096)

    Published 2022
    “…Background<p>With the unveiling of new mechanisms and the advent of new drugs, the prognosis of diffuse large B-cell lymphoma (DLBCL) becomes promising, but some patients still progress to the relapse or refractory stage. …”
  20. 140

    Table1_Inhibition of CISD2 enhances sensitivity to doxorubicin in diffuse large B-cell lymphoma by regulating ferroptosis and ferritinophagy.docx by Chaofeng Zhang (845343)

    Published 2024
    “…Background<p>CDGSH iron-sulfur domain 2 (CISD2), an iron-sulfur protein with a [2Fe-2S] cluster, plays a pivotal role in the progression of various cancers, including Diffuse Large B-cell Lymphoma (DLBCL). …”